COVID-19: “Aiming for early approval” such as ivermectin: Prime Minister Abe declares
COVID-19:
May 14: Press conference
At a press conference on May 14, Prime Minister Shinzo Abe referred to the development of a new drug for coronavirus infection.
“Abigan” (generic name: Fabipiravir)
We have clearly stated, “The idea we aim for approval within May 2020”.
Candidate anti-influenza virus drugs:
In addition, Prime Minister Abe expressed his desire to obtain early approval for the following three candidate drugs.
▽ Nichiiko: Proteolytic enzyme inhibitor / fusan (generic name: nafamostat mesylate)
▽ Chugai: Humanized anti-human IL-6 receptor monoclonal antibody / Actemra (generic name: tocilizumab [genetical recombination])
▽ MSD: anthelmintic / stromethol (generic name: ivermectin)
“We will aim for early regulatory approval as soon as the efficacy is confirmed.”
All of the above 4 drugs are drugs found by Japan.
In the future, the therapeutic effect of the combination can be expected.
The safety has already been confirmed, as side effects have been found as therapeutic agents for other diseases.
WebMedical Bulletin | Nippon Medical Bulletin